Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-APlus: Adjuvant Dabrafenib + Trametinib Pyrexia Management
NCT03551626Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of dabrafenib + trametinib and trametinib in cutaneous melanoma (CM), sponsored by Novartis. Primary endpoint: Composite Rate of Pyrexia Related Events at 12 months. Started Aug 2018; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03551626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551626.